Unlock instant, AI-driven research and patent intelligence for your innovation.

Hypodermic injection in-situ gel for treating osteosarcomas

A technology of subcutaneous injection and in situ gel, applied in the field of medicine, can solve the problems of less than 20% survival rate and inconvenient life of patients

Inactive Publication Date: 2016-06-22
杜峰
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Before the 1970s, osteosarcoma was generally treated with amputation, but the 5-year survival rate was still less than 20%, and amputation brought great inconvenience to the lives of patients.
However, so far, there is still a lack of ideal drugs that can reduce the toxicity of doxorubicin while maintaining or enhancing its efficacy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Hypodermic injection in-situ gel for treating osteosarcomas
  • Hypodermic injection in-situ gel for treating osteosarcomas
  • Hypodermic injection in-situ gel for treating osteosarcomas

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Example 1 Preparation of in situ gel for subcutaneous injection for the treatment of osteosarcoma

[0024] 1) Take 280g of doxorubicin hydrochloride and 20g of HIV-1-TAT protein 47-57 polypeptide fragment, add deionized water to make preparation A, and the concentration of doxorubicin in preparation A is 10mg / ml;

[0025] 2) Add poloxamer P407, poloxamer P188, and hydroxypropyl methylcellulose K4M to the solution A in sequence, stir well, and disperse evenly to obtain the solution B. The amount of poloxamer P407 in the solution B is The percentage by weight is 20%, the percentage by weight of Poloxamer P188 is 1.2%, and the percentage by weight of hydroxypropyl methylcellulose K4M is 0.3%;

[0026] 3) Swell the solution B at 4°C for 24 hours, pass it through a 0.22 μm microporous membrane, and dispense it.

Embodiment 2

[0027] Example 2 Preparation of in situ gel for subcutaneous injection for the treatment of osteosarcoma

[0028] 1) Take 480g of doxorubicin hydrochloride and 30g of HIV-1-TAT protein 47-57 polypeptide fragment, add deionized water to make a solution A, and the concentration of doxorubicin in the solution A is 10mg / ml;

[0029] 2) Add poloxamer P407, poloxamer P188, and hydroxypropyl methylcellulose K4M to the solution A in sequence, stir well, and disperse evenly to obtain the solution B. The amount of poloxamer P407 in the solution B is The percentage by weight is 20%, the percentage by weight of Poloxamer P188 is 1.2%, and the percentage by weight of hydroxypropyl methylcellulose K4M is 0.3%;

[0030] 3) Swell the solution B at 4°C for 24 hours, pass it through a 0.22 μm microporous membrane, and dispense it.

Embodiment 3

[0031] Example 3 Preparation of in situ gel for subcutaneous injection for the treatment of osteosarcoma

[0032] 1) Take 340g of doxorubicin hydrochloride and 20g of HIV-1-TAT protein 47-57 polypeptide fragments, add deionized water to make solution A, and the concentration of doxorubicin in solution A is 10mg / ml;

[0033] 2) Add poloxamer P407, poloxamer P188, and hydroxypropyl methylcellulose K4M to the solution A in sequence, stir well, and disperse evenly to obtain the solution B. The amount of poloxamer P407 in the solution B is The percentage by weight is 20%, the percentage by weight of Poloxamer P188 is 1.2%, and the percentage by weight of hydroxypropyl methylcellulose K4M is 0.3%;

[0034] 3) Swell the solution B at 4°C for 24 hours, pass it through a 0.22 μm microporous membrane, and dispense it.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medicines, in particular to a hypodermic injection in-situ gel for treating osteosarcomas. The hypodermic injection in-situ gel for treating the osteosarcomas is prepared from pharmaceutically acceptable auxiliary materials and raw materials in parts by weight as follows: 25-50 parts of doxorubicin hydrochloride and 1-4 parts of HIV-1-TAT protein 47-57 polypeptide fragments. The in-situ gel prepared from the raw materials, poloxamer P407, poloxamer P188, hydroxypropyl methyl cellulose K4M and deionized water has the good slow-release effect. The HIV-1-TAT protein 47-57 polypeptide fragments can significantly improve the anti-tumor effect of doxorubicin hydrochloride and reduce the toxic effect of doxorubicin hydrochloride.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to an in situ gel for subcutaneous injection used for treating osteosarcoma. Background technique [0002] Osteosarcoma is a common primary bone malignancy in children and adolescents, with an incidence rate of about 3 / 1 million, of which about 80% to 90% of osteosarcoma occurs in the metaphysis of the long tubular bones of the extremities, especially the distal femur and tibia. Proximal and proximal humerus. Before the 1970s, osteosarcoma was generally treated with amputation, but the 5-year survival rate was still less than 20%, and amputation brought great inconvenience to the lives of patients. [0003] The emergence of chemotherapy drugs provides a new method for the treatment of osteosarcoma. Doxorubicin, cisplatin, methotrexate, vincristine, and cyclophosphamide all have good therapeutic effects on osteosarcoma, and can significantly prolong the survival of osteosarcoma ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/08A61K9/06A61P35/00A61K31/704
CPCA61K9/0024A61K9/06A61K31/704A61K38/08A61K47/10A61K47/38A61K2300/00
Inventor 杜峰
Owner 杜峰